Cargando…

Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure

Acute heart failure (AHF) is the most common primary diagnosis for hospitalized heart diseases in Africa. As increased fatty acid β-oxidation (FAO) during heart failure triggers detrimental effects on the myocardium, we hypothesized that trimetazidine (TMZ) (partial FAO inhibitor) offers cardioprote...

Descripción completa

Detalles Bibliográficos
Autores principales: Breedt, Emilene, Lacerda, Lydia, Essop, M. Faadiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478112/
https://www.ncbi.nlm.nih.gov/pubmed/28632748
http://dx.doi.org/10.1371/journal.pone.0179509
_version_ 1783244897950629888
author Breedt, Emilene
Lacerda, Lydia
Essop, M. Faadiel
author_facet Breedt, Emilene
Lacerda, Lydia
Essop, M. Faadiel
author_sort Breedt, Emilene
collection PubMed
description Acute heart failure (AHF) is the most common primary diagnosis for hospitalized heart diseases in Africa. As increased fatty acid β-oxidation (FAO) during heart failure triggers detrimental effects on the myocardium, we hypothesized that trimetazidine (TMZ) (partial FAO inhibitor) offers cardioprotection under normal and obese-related diabetic conditions. Hearts were isolated from 12-14-week-old obese male and female diabetic (db/db) mice versus lean non-diabetic littermates (db/+) controls. The Langendorff retrograde isolated heart perfusion system was employed to establish an ex vivo AHF model: a) Stabilization phase—Krebs Henseleit buffer (10 mM glucose) at 100 mmHg (25 min); b) Critical Acute Heart Failure (CAHF) phase–(1.2 mM palmitic acid, 2.5 mM glucose) at 20 mmHg (25 min); and c) Recovery Acute Heart Failure phase (RAHF)–(1.2 mM palmitic acid, 10 mM glucose) at 100 mmHg (25 min). Treated groups received 5 μM TMZ in the perfusate during either the CAHF or RAHF stage for the full duration of each respective phase. Both lean and obese males benefited from TMZ treatment administered during the RAHF phase. Sex differences were observed only in lean groups where the phases of the estrous cycle influenced therapy; only the lean follicular female group responded to TMZ treatment during the CAHF phase. Lean luteal females rather displayed an inherent cardioprotection (without treatments) that was lost with obesity. However, TMZ treatment initiated during RAHF was beneficial for obese luteal females. TMZ treatment triggered significant recovery for male and obese female hearts when administered during RAHF. There were no differences between lean and obese male hearts, while lean females displayed a functional recovery advantage over lean males. Thus TMZ emerges as a worthy therapeutic target to consider for AHF treatment in normal and obese-diabetic individuals (for both sexes), but only when administered during the recovery phase and not during the very acute stages.
format Online
Article
Text
id pubmed-5478112
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-54781122017-07-05 Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure Breedt, Emilene Lacerda, Lydia Essop, M. Faadiel PLoS One Research Article Acute heart failure (AHF) is the most common primary diagnosis for hospitalized heart diseases in Africa. As increased fatty acid β-oxidation (FAO) during heart failure triggers detrimental effects on the myocardium, we hypothesized that trimetazidine (TMZ) (partial FAO inhibitor) offers cardioprotection under normal and obese-related diabetic conditions. Hearts were isolated from 12-14-week-old obese male and female diabetic (db/db) mice versus lean non-diabetic littermates (db/+) controls. The Langendorff retrograde isolated heart perfusion system was employed to establish an ex vivo AHF model: a) Stabilization phase—Krebs Henseleit buffer (10 mM glucose) at 100 mmHg (25 min); b) Critical Acute Heart Failure (CAHF) phase–(1.2 mM palmitic acid, 2.5 mM glucose) at 20 mmHg (25 min); and c) Recovery Acute Heart Failure phase (RAHF)–(1.2 mM palmitic acid, 10 mM glucose) at 100 mmHg (25 min). Treated groups received 5 μM TMZ in the perfusate during either the CAHF or RAHF stage for the full duration of each respective phase. Both lean and obese males benefited from TMZ treatment administered during the RAHF phase. Sex differences were observed only in lean groups where the phases of the estrous cycle influenced therapy; only the lean follicular female group responded to TMZ treatment during the CAHF phase. Lean luteal females rather displayed an inherent cardioprotection (without treatments) that was lost with obesity. However, TMZ treatment initiated during RAHF was beneficial for obese luteal females. TMZ treatment triggered significant recovery for male and obese female hearts when administered during RAHF. There were no differences between lean and obese male hearts, while lean females displayed a functional recovery advantage over lean males. Thus TMZ emerges as a worthy therapeutic target to consider for AHF treatment in normal and obese-diabetic individuals (for both sexes), but only when administered during the recovery phase and not during the very acute stages. Public Library of Science 2017-06-20 /pmc/articles/PMC5478112/ /pubmed/28632748 http://dx.doi.org/10.1371/journal.pone.0179509 Text en © 2017 Breedt et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Breedt, Emilene
Lacerda, Lydia
Essop, M. Faadiel
Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure
title Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure
title_full Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure
title_fullStr Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure
title_full_unstemmed Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure
title_short Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure
title_sort trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478112/
https://www.ncbi.nlm.nih.gov/pubmed/28632748
http://dx.doi.org/10.1371/journal.pone.0179509
work_keys_str_mv AT breedtemilene trimetazidinetherapyfordiabeticmouseheartssubjectedtoexvivoacuteheartfailure
AT lacerdalydia trimetazidinetherapyfordiabeticmouseheartssubjectedtoexvivoacuteheartfailure
AT essopmfaadiel trimetazidinetherapyfordiabeticmouseheartssubjectedtoexvivoacuteheartfailure